2037-99-2

Basic information

• Product Name: 3-benzyl-2H-1,3-benzoxazine-2,4(3H)-dione
• Synonyms: 3-Benzyl-benzo[e][1,3]oxazine-2,4-dione
• CAS NO: 2037-99-2
• Molecular Formula: C₁₅H₁₁NO₃
• Molecular Weight: 253.2527
• Mol File: 2037-99-2.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 419.5°C at 760 mmHg
• Flash Point: 207.5°C
• Density: 1.335g/cm³
• Vapor Pressure: 3.03E-07mmHg at 25°C
• Refractive Index: 1.64
• CAS DataBase Reference: 3-benzyl-2H-1,3-benzoxazine-2,4(3H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 3-benzyl-2H-1,3-benzoxazine-2,4(3H)-dione(2037-99-2)
• EPA Substance Registry System: 3-benzyl-2H-1,3-benzoxazine-2,4(3H)-dione(2037-99-2)

Safety Data

• Hazardous Substances Data: 2037-99-2(Hazardous Substances Data)

Upstream product

• 100-44-7 benzyl chloride 
• 938-41-0 benzo[e][1,3]oxazine-2,4-dione; sodium salt 
• 622-78-6 Benzyl isothiocyanate 
• 69-72-7 salicylic acid 
• 201230-82-2 carbon monoxide 
• 16188-57-1 2-iodo-4-methylphenol 
• 3173-56-6 benzyl isothiocyanate 
• 79960-76-2 (2-ethoxycarbonyloxy-benzoyl)-carbonic acid ethyl ester 
• 100-46-9 benzylamine 
• 20919-36-2 N-benzylsalicylamide 
• 541-41-3 chloroformic acid ethyl ester 
• 2037-95-8 1,3-benzoxazine-2,4-dione 
• 1381926-83-5 (R,E)-4-((R)-1-(7-ethoxy-7-oxoheptyl)-5-oxopyrrolidin-2-yl)-1,1-difluoro-1-phenylbut-3-en-2-yl 2-hydroxybenzoate 
• 5538-51-2 O-acetylsalicyloyl chloride 

Downstream Products

• 20919-36-2 N-benzylsalicylamide 

Relevant articles and documents

Design and synthesis of novel bone-targeting dual-action pro-drugs for the treatment and reversal of osteoporosis

There is an important medical need for effective therapies to redress the general bone loss associated with advanced osteoporosis. Prostaglandin E 2 and related EP4 receptor agonists have been shown to stimulate bone regrowth but their use has been limited by systemic side effects. Herein is described the design and synthesis of novel dual-action bone-targeting conjugate pro-drugs where two classes of active agents, a bone growth stimulating prostaglandin E2 EP4 receptor subtype agonist (5 or 6) and a bone resorption inhibitor bisphosphonate, alendronic acid (1), are coupled using metabolically labile carbamate or 4-hydroxyphenylacetic acid based linkers. Radiolabelled conjugates 9, 11a/b and 25 were synthesized and evaluated in vivo in rats for uptake of the conjugate into bone and subsequent release of the EP4 agonists over time. While conjugate 11a/b was taken up (9.0% of initial dose) but not released over two weeks, conjugates 9 and 25 were absorbed at 9.4% and 5.9% uptake of the initial dose and slowly released with half-lives of approximately 2 weeks and 5 days respectively. These conjugates were well tolerated and offer potential for sustained release and dual synergistic activity through their selective bone targeting and local release of the complimentary active components.

N-alkylation of imides using phase transfer catalysts under solvent-free conditions

(Chemical Equation Presented) N-Alkylation of imides in the reaction of imides and alkylhalides, catalyzed by PT catalysts under solvent-free conditions, has been developed. The reaction occurs in the presence of K 2CO3, and in many cases it takes place spontaneously. In the N-benzylation reaction, it has been recognized that TBAB (tetrabutylammonium bromide) and TBATFB (tetrabutylammonium tetrafluoroborate) show highest catalytic effect. Versatility and synthetic capacity of the solvent-free alkylation has been confirmed by N-benzylation and N-ethylation of various imides. The developed procedure gives easy access to N-(ω-bromoalkyl) imides.

A simple one-pot synthesis of benzoxazine-2,4-diones and benzothiazine-2,4-diones

A simple and efficient procedure has been developed for a one-pot synthesis of substituted benzoxazine-2,4-diones and benzothiazine-2,4-diones directly from salicylic acid (or thiosalicylic acid) and amines.